



Patent
Attorney Docket No. 82182
Customer No. 23685

TRANSMITTAL LETTER

Inventor: Helga Schleenhain
Serial No: 10/542,279
Filed: July 15, 2005
For: COMBINATION PREPARATION AGAINST VERTIGO

Examiner: Samira Jm Jean-Louis
Group Art Unit: 4173
Confirmation No: 8066

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

Transmitted herewith for the above-identified patent application are the following:

An Information Disclosure Statement
PTO Form PTO/SB/08B
Copies of 6 documents
A check for \$180 (information disclosure statement fee)
A return postcard

The item(s) checked below are appropriate:

an
1755.

- Applicant(s) hereby petition(s) for a () month extension of time to respond to
- Please charge any fees or costs not accounted for to Deposit Account No. 11-
- Applicant is a small entity.

Date: April 16, 2008

Edward M. Kriegsman
Reg. No. 33,529

KRIEGSMAN & KRIEGSMAN
30 Turnpike Road, Suite 9
Southborough, MA 01772
(508) 481-3500

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Mail Stop Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on April 16, 2008.

Edward M. Kriegsman



PATENT
Attorney Docket No. 82182
Customer No. 23685

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:)
)
 HELGA SCHLEENHAIN)
)
 Serial No.: 10/542,279) Group Art Unit: 4173
)
 Filed: July 15, 2005) Examiner: Samira JM Jean-Louis
)
 For: COMBINATION PREPARATION) Confirmation Number: 8066
 AGAINST VERTIGO)

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

INFORMATION DISCLOSURE STATEMENT

In accordance with the provisions of 37 C.F.R. 1.56, 1.97 and 1.98, Applicant discloses the following information:

1. Scholtz et al., "Treatment of Vertigo Due to Acute Unilateral Vestibular Loss with a Fixed Combination of Cinnarizine and Dimenhydrinate: A Double-Blind, Randomized, Parallel-Group Clinical Study," Clinical Therapeutics, 26(6):866-77 (2004) (cited in International Search Report and discussed in the Amendment filed April 14, 2008);

2. Cirek et al., "Efficacy and Tolerability of a Fixed Combination of Cinnarizine and Dimenhydrinate versus Betahistine in the Treatment of Otogenic Vertigo," Clin. Drug Invest., 25(6):377-89 (2005) (discussed in the Amendment filed April 14, 2008);

3. "Dimenhydrinat kombiniert mit Cinnarizin hilft," Therapiewoche, 46(3):175 (1996) (cited in the International Search Report);

4. Novotný et al., "The Efficacy of Arlevert Therapy for Vertigo and Tinnitus," International Tinnitus Journal, 5(1):60-2 (1999) (cited in the International Search Report);

5. "Schwindeltherapie mit Cinnarizin und Dimenhydrinat: Kombinationsbehandlung ist effektiver," T&E Neurologie Psychiatrie, 11(12):927-8 (1997) (cited in International Search Report); and

04/18/2008 CHNGUYEN2 00000017 10542279

6. Novotný et al., "Fixed Combination of Cinnarizine and Dimenhydrinate Versus Betahistine Dimesylate in the Treatment of Ménière's Disease: A Randomized, Double-Blind, Parallel Group Clinical Study," International Tinnitus Journal, 8(2):115-23 (2002) (cited in International Search Report).

Copies of the above documents are provided with this paper. In addition, all of the above documents are listed on the enclosed PTO Form PTO/SB/08B. Applicant respectfully requests that the Examiner consider the above-listed documents and evidence that consideration by making appropriate notations on the enclosed forms.

This submission does not represent that a search has been made or that no better prior art exists and does not constitute an admission that the above-listed documents constitute "prior art."


Applicant reserves the right to take appropriate action to establish the patentability of the disclosed invention over the above-listed documents, should the documents be applied against the claims of the present invention.

A check in the amount of \$180 is enclosed herewith. If there are any other fees due in connection with the filing of this paper that are not accounted for, the Examiner is authorized to charge the fees to our Deposit Account No. 11-1755. If a fee is required for an extension of time

under 37 C.F.R. 1.136 that is not accounted for already, such an extension of time is requested and the fee should also be charged to our Deposit Account.


Respectfully submitted,

Kriegsman & Kriegsman

By: 
Edward M. Kriegsman
Reg. No. 33,529
30 Turnpike Road, Suite 9
Southborough, MA 01772
(508) 481-3500

Dated: April 16, 2008

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Mail Stop Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on April 16, 2008.


Edward M. Kriegsman